NCT06078982View on ClinicalTrials.gov

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Gastric CancerHER2-low-expressing Gastric Cancer
Interventions
DRUG

Disitamab Vedotin

2.0mg/kg, intravenously D1, once every 14 days (Q2W)

DRUG

Toripalimab

3.0 mg/kg, once every 14 days (Q2W)

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shanghai East Hospital

OTHER